Tu banner alternativo

Topiroxostat

The Topiroxostat issue is one that has captured the attention of many as of late. Its relevance and impact on different aspects of daily life make it a topic of widespread interest. From its origin to its future implications, Topiroxostat has generated debates, discussions and analyzes in various areas. In this article, we will thoroughly explore all aspects related to Topiroxostat, analyze its influence on today's society and reflect on its possible developments in the future. Join us on this journey of discovery and inquiry around Topiroxostat.

Tu banner alternativo
Topiroxostat
Clinical data
Trade namesTopiloric, Uriadec
ATC code
  • None
Legal status
Legal status
  • Approved in Japan
Identifiers
  • 4--2-pyridinecarbonitrile
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H8N6
Molar mass248.249 g·mol−1
3D model (JSmol)
  • C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
  • InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
  • Key:UBVZQGOVTLIHLH-UHFFFAOYSA-N

Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia.[1] It was approved for use in Japan in June 2013.[1]

Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.[2]

References

  1. ^ a b New Drugs FY2013 (PDF), Pharmaceuticals and Medical Devices Agency, Japan, archived from the original (PDF) on 2014-02-22
  2. ^ Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. (December 2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. 18 (6): 876–84. doi:10.1007/s10157-014-0935-8. PMC 4271138. PMID 24448692.
Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia